Amplyx Pharmaceuticals, a San Diego-based drug developer, has raised an initial round of $1.5 million in financing. The investors included Golden Seeds, Life Science Angels, and Tech Coast Angels. The company, led by CEO Elaine Heron, is developing technology to improve existing drugs by controlling their concentration and time they hit their targets, according to a statement. The company noted that Golden Seeds is a national angel investment network that invests in women-led companies.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
